Revenue is expanding its overseas share, illustrating a balance between domestic market growth and overseas sales. The 2026 Q2 consolidated results disclose trends in revenue and profit, segment-wise movements, and cash flow and balance sheet status. Progress toward the medium-term plan and future overseas expansion strategies are also clarified.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"5187","jir_company_name":"Create Medic Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/5187-20260807-01.pdf","jir_short_summary":"Revenue is expanding its overseas share, illustrating a balance between domestic market growth and overseas sales. The 2026 Q2 consolidated results disclose trends in revenue and profit, segment-wise movements, and cash flow and balance sheet status. Progress toward the medium-term plan and future overseas expansion strategies are also clarified.","jir_summary":"### Section Heading\nThis fiscal report, as a consolidated results report, discloses trends in key indicators such as revenue, gross profit, and operating profit. It also presents segment-wise revenue composition, trends in cost of sales and selling, general and administrative expenses, and cash flow status. Highlights include overseas market expansion strategy and progress of the medium-term plan.\n\n### Section 2 Heading\nAs for outlook, the plan to balance higher overseas revenue share with stable growth in the domestic market is described. Based on the medium-term management plan, the document outlines capital allocation, investment plans, expansion of R&D and manufacturing capacity, and efforts to curb SG&A, aiming to balance financial soundness with growth potential.","jir_financial_highlights":"Revenue: 6,932\u767e\u4e07\u5186 (+)\nCost of Revenue: 4,113\u767e\u4e07\u5186 (+)\nOperating Profit: 336\u767e\u4e07\u5186","jir_category":"","jir_hashtags":"#CreateMedicNotForIRContent #NotRelevantToTreasuryStockBuybacksOrExecutiveAppointments","jir_key_figures":"Revenue: 6,932\u767e\u4e07\u5186\nCost of Revenue: 4,113\u767e\u4e07\u5186\nOperating Profit: 336\u767e\u4e07\u5186","jir_meta_title":"[Create Medic] 2026 Q2 Results \u2014 Revenue 6,932 million yen, Operating Profit 336 million yen","jir_meta_description":"Summary of Create Medic's 2026 Q2 consolidated results. Explanations of trends in revenue, cost of sales, operating profit, segment movements, cash flow, and progress on overseas expansion and the medium-term plan.","jir_og_title":"Key Points from 2026 Q2 Consolidated Results for Create Medic","jir_og_description":"The Q2 consolidated results outline trends in revenue, costs, and profit, along with progress on overseas strategy. Explanations of medium-term plan progress and future investment guidance.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":59045,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-98249","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n